INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference

Stock Information for NanoVibronix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NanoVibronix Inc.

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes
INmune Bio's CaRe PC Trial of INKmune(TM) in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro(TM) Presented at the Alzheimer's Association International Conference
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro(TM) at the Alzheimer's Association International Conference
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro(TM) in Early Alzheimer's Disease
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.